LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management
Ballerup, Denmark, May 10, 2019 – LEO Pharma A/S, a global leader in medical dermatology, today announced the appointment of Beth-Anne Lang, Vice President and Head of Global Regulatory Affairs and Christine Garrett, Vice President and Head of Global Project Manage-ment. Both will join LEO Pharma on May 13.
Beth-Anne Lang and Christine Garrett will be based in Madison, New Jersey and be part of LEO Pharma’s Global Development Team. Beth-Anne’s main responsibility will be to lead and transform the regulatory into an even more modern and global organization and in this way support and accelerate LEO Pharma’s development of innovative dermatologic therapies to patients around the world. Christine Garrett’s main responsibility will be to lead a new program management organisation which will be key for LEO Pharma in order to strengthen the company’s global drug development capabilities and help make innovation available to patients faster.
LEO Pharma’s Global Development Team plays an important role in the execution of the company’s 2025 strategy. As part of the strategy, LEO Pharma R&D has launched a series of initiatives to raise the bar scientifically and build new capabilities within rare diseases, disease understanding and precision medicine within the company – supported by new ways of working with data and advanced analytics. Among other, this includes the recent addition of a new Translational Medicine Unit in Boston.
“LEO Pharma is building the world’s best dermatology R&D organisation, nothing less. The appointment of Beth-Anne Lang and Christine Garrett is a key milestone in achieving this ambition. Beth-Anne and Christine’s vast experience with global leadership roles in multi-country cross functional teams and diverse portfolios combined with their strong technical and scientific backgrounds will be critical in our constant quest for improving science to the benefit of patients,” says Christian Antoni, Head of Development, LEO Pharma.
Beth-Anne Lang comes to LEO Pharma with a broad regulatory experience in early and late development across several therapeutic areas and in biologics. Beth-Anne joins LEO Pharma from Takeda, where she has held a number of regulatory positions of increasing responsibility over the past 17 years, most recently as Vice President, Global Regulatory Affairs for marketed products. Among other, she has been a key driver in creating Takeda’s global regulatory strategies across multiple therapeutic areas and building the marketed products regulatory organization. She holds a Master in Business Administration from Marquette University and a Bachelor of Science in Food Science/Microbiology from the University of Illinois.
Christine Garrett joins LEO Pharma from a position as Global Project Leader for research & early development programs. Prior to this, she spent more than 16 years at Novartis in broad therapeutic areas across all phases of development, where she among other successfully built and led global project teams and cross-functional teams across research, development and commercial. Christine holds a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology, a Post-Graduate Certificate in Pharma Business Development & Licensing from the University of Manchester, A Master’s Certificate in Applied Project Management from Villanova University as well as Bachelor of Science in Chemistry from the Rochester Institute of Technology.
For further information, please contact:
LEO Pharma A/S
Trine Juul Wengel; Global External Communications
Tel.: +45 72 60 86 18
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million. For more information, go to: www.linkedin.com/company/leo-pharma or www.leo-pharma.com
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma completes the acquisition of Bayer’s pre-scription dermatology business2.7.2019 09:00:00 CEST | Press release
LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO Pharma. The companies first announced the proposed transaction on July 31, 2018 and completed the first step of the acquisition with the closing in the United States on September 4, 2018. Today’s second and final closing covers all other countries.
LEO Pharma udnævner Catherine Mazzacco som ny CEO3.6.2019 09:00:00 CEST | Pressemeddelelse
Ballerup, den 3. juni 2019. LEO Pharma offentliggjorde i dag, at Gitte Aabo efter 27 år i virksomheden – og heraf de seneste 11 som adm. direktør – træder tilbage fra posten som øverste chef den 31. juli 2019. Bestyrelsen har udpeget Catherine Maz-zacco som ny adm. direktør med tiltrædelse 1. august.
New General Manager appointed to lead LEO Pharma across the Nordic region1.5.2019 10:12:37 CEST | Press release
Klaus Abel arrives to take the regional helm of the global medical dermatology leader
New data show that LEO Pharma’s Kyntheum® (brodalumab) sustains PASI 100 scores longer than ustekinumab for people with moderate-to-severe plaque psoriasis25.4.2019 09:12:24 CEST | Press release
Ballerup, Denmark, April 25, 2019: LEO Pharma A/S, a global leader in medical dermatology, today announced that new data presented this week at the 6th Congress of the Skin Inflammation and Psoriasis International Network (SPIN) in Paris demonstrate that more patients with moderate-to-severe psoriasis who received treatment with brodalumab maintained a PASI (Psoriasis Area Severity Index) 100 score for longer than those who were treated with ustekinumab over 52 weeks.
LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases11.4.2019 11:40:51 CEST | Press release
The large-scale IMI project will investigate the causes and mechanisms of Atopic Dermatitis and Psoriasis
LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology9.4.2019 10:00:56 CEST | Pressemeddelelse
Ballerup, April 9, 2019: LEO Pharma A/S, a global leader in medical dermatology and Elektrofi, a Boston- based biotechnology company focused on drug formulation and delivery innovations, today announced an expansion of the two companies’ partnership agreement (signed in 2017) to further include antibodies from LEO Pharma’s pipeline with the aim of achieving improvements in drug delivery within dermatology.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom